Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not on...

Full description

Bibliographic Details

Published in:	Cancer cell 2006-07, Vol.10 (1), p.39-50
Main Authors:	Zhou, Bin-Bing S., Peyton, Michael, He, Biao, Liu, Changnian, Girard, Luc, Caudler, Eian, Lo, Yvonne, Baribaud, Frederic, Mikami, Iwao, Reguart, Noemi, Yang, Gengjie, Li, Yanlong, Yao, Wenqing, Vaddi, Kris, Gazdar, Adi F., Friedman, Steven M., Jablons, David M., Newton, Robert C., Fridman, Jordan S., Minna, John D., Scherle, Peggy A.
Format:	Article
Language:	eng
Subjects:	ADAM Proteins - antagonists & inhibitors ADAM Proteins - genetics ADAM Proteins - metabolism ADAM17 Protein Animals Apoptosis - drug effects Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - metabolism Cell Line, Tumor Female Gene Expression - genetics Humans Ligands Mice Mice, Inbred BALB C Mice, Nude Models, Biological Paclitaxel - pharmacology Piperidines - pharmacology Piperidines - therapeutic use Protease Inhibitors - pharmacology Protease Inhibitors - therapeutic use Protein Kinase Inhibitors - pharmacology Quinazolines - pharmacology Receptor, Epidermal Growth Factor - genetics Receptor, Epidermal Growth Factor - metabolism Receptor, ErbB-3 - metabolism Signal Transduction - drug effects SIGNALING Spiro Compounds - pharmacology Spiro Compounds - therapeutic use Xenograft Model Antitumor Assays
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!